Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists

Journal of Medicinal Chemistry

Volumn 49, Issue 6, 2006, Pages 2022-2027

  Raitio, Katri H ^a   Savinainen, Juha R ^a   Vepsäläinen, Jouko ^a   Laitinen, Jarmo T ^a   Poso, Antti ^a   Järvinen, Tomi ^a   Nevalainen, Tapio ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

2 BENZO[1,3]DIOXOL 5 YL N (7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLIN 3 YL)ACETAMIDE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID (2 AMINOPHENYL)AMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID (3 PHENYLPROPYL)AMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID 3,4 DIHYDROXYBENZYLAMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID [2 (1H INDOL 3 YL)ETHYL]AMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID [2 (3,4 DIHYDROXYPHENYL)ETHYL]AMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID [2 (4 AMINOPHENYL)ETHYL]AMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID [2 (4 CHLOROPHENYL)ETHYL]AMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID [2 (4 HYDROXYPHENYL)ETHYL]AMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID [2 (4 NITROPHENYL)ETHYL]AMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID BENZYLAMIDE; 7 METHOXY 2 OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID PHENETHYLAMIDE; 7 METHOXY 2OXO 8 PENTYLOXY 1,2 DIHYDROQUINOLINE 3 CARBOXYLIC ACID N BENZO[1,3]DIOXOL 5 YLMETHYL)AMIDE; AMIDE; CANNABINOID 2 RECEPTOR INVERSE AGONIST; CANNABINOID RECEPTOR AGONIST; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); JTE 907; QUINOLINE DERIVATIVE; SULFUR 35; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING ASSAY; CELL MEMBRANE; CEREBELLUM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; GENETIC TRANSFECTION; NERVE CELL MEMBRANE; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; BORNANES; CHO CELLS; CRICETINAE; CRICETULUS; DIOXOLES; HUMANS; PYRAZOLES; QUINOLONES; RADIOLIGAND ASSAY; RECEPTOR, CANNABINOID, CB2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33645423157     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050879z     Document Type: Article

References (21)

1. Munro, S.; Thomas, K. L.; Abu-Shaar, M.; Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365, 61-65.
2. Galiègue, S.; Mary, S.; Marchand, J.; Carrière, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem. 1995, 232, 54-61.
3. Felder, C. C.; Joyce, K. E.; Briley, E. M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A. L.; Mitchell, R. L.; Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 1995, 48, 443-450.
4. Bouaboula, M.; Poinot-Chazel, C.; Marchand, J.; Canat, X.; Bourrié, B.; Rinaldi-Carmona, M.; Calandra, B.; Le Fur, G.; Casellas, P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem. 1996, 237, 704-711.
5. Malan, T. P., Jr.; Ibrahim, M. M.; Deng, H.; Liu, Q.; Mata, H. P.; Vanderah, T.; Porreca, F.; Makriyannis, A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 2001, 93, 239.
6. Raitio, K. H.; Salo, O. M. H.; Nevalainen, T.; Poso, A.; Jarvinen, T. Targeting the cannabinoid CB2 receptor: Mutations, modeling and development of CB2 selective ligands. Curr. Med. Chem. 2005, 12, 1217-1237.
7. Iwamura, H.; Suzuki, H.; Ueda, Y.; Kaya, T.; Inaba, T. In Vitro and in Vivo Pharmacological Characterization of JTE-907, a Novel Selective Ligand for the Cannabinoid CB2 Receptor. J. Pharmacol. Exp. Ther. 2000, 296, 420-425.
8. Kenakin, T. Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol. 2004, 65, 2-11.
9. Costa, T.; Herz, A. Antagonists with negative intrinsic activity at δ opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. 1989, 86, 7321-7325.
10. Inaba, T.; Kaya, T.; Iwamura, H. 2-Oxoquinoline compounds and medicinal uses thereof. WO Patent 00/40562, 2000.
11. Savinainen J. R.; Kokkola, T.; Salo, O. M.; Poso, A.; Järvinen, T.; Laitinen, J. T. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. Br. J. Pharmacol 2005, 145, 636-645.
12. Fukuyama, Y.; Iwatsuki, C.; Kodama, M.; Ochi, M.; Kataoka, K.; Shibata, K. Antimicrobial indolequinones from the mid-intestinal gland of the muricid gastropod Drupella fagum. Tetrahedron 1998, 54, 10007-10016.
13. Riesgo, E. C.; Jin, X.; Thummel, R. P. Introduction of benzo[h]-quinoline and 1, 10-phenanthroline subunits by Friedländer methodology. J. Org. Chem. 1996, 61, 3017-3022.
14. Leone-Bay, A.; Paton, D. R.; Freeman, J.; Lercara, C.; O'Toole, D. Gschneider, D.; Wang, E.; Harris, E.; Rosado, C.; Rivera, T. DeVincent, A.; Tai, M.; Mercogliano, F.; Agarwal, R.; Leipold, H. Baughman, R. A. Synthesis and evaluation of compounds that facilitate the gastrointestinal absorption of heparin. J. Med. Chem. 1998, 41, 1163-1171.
15. Holy, P.; Sehnal, P.; Tichý, M.; Závada, J.; Císarová, I. Self-assembly of chiral hydrogen-bonded grid layers from terephthalic Siamese twins. Tetrahedron: Asymmetry 2003, 14, 245-253.
16. Wallis, e. S.; Moyer, W. W. Molecular rearrangements involving optically active radicals. IV. The Hofmann rearrangement of the amide of an optically active 2,2′-disubstituted 6-arbodioxyphenyl. J. Am. Chem. Soc. 1933, 55, 2598-2603.
17. Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S.; McCallion, D.; Pertwee, R.; Makriyannis. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 1999, 42, 769-776.
18. Salo, O. M. H.; Raitio, K.; Savinainen, J. R.; Nevalainen, T.; Lahtela-Kakkonen, M.; Laitinen, J. T.; Järvinen, T.; Poso, A. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J. Med. Chem. 2005, 48, 7166-7171.
19. Zhang, R.; Hurst, D. P.; Barnett-Norris, J.; Reggio, P. H.; Song, Z. Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: Evidence for possible CB2 deviation from a rhodopsin template. Mol. Pharmacol. 2005, 68, 69-83.
20. Savinainen, J. R.; Järvinen, T.; Laine, K.; Laitinen, J. T. Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB1 receptor-dependent G-protein activation in rat cerebellar membranes. Br. J. Pharmacol. 2001, 134, 664-672.
21. Savinainen, J. R.; Saario, S. M.; Niemi, R.; Järvinen, T.; Laitinen, J. T. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine AI and cannabinoid CB1 receptors. Br. J. Pharmacol. 2003, 140, 1451-1459.